In order to validate CD15 as a clinically applicable marker of PAICs, we performed in silico analyses on a non-overlapping cohort of PAs for which gene expression profiles were curated for non-malignant pituitary glands, primary adenomas, and their recurrent tumors [16] (Fig. 6c). This evidence concerns the gene FUT4 and adenoma.